Evidence map›Paper›PMID 32421364›Full record

ArticleExpert opinion on drug discovery2020

Challenges identifying efficacious miRNA therapeutics for cancer.

Meirav Segal, Frank J Slack

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on drug discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  12. Challenges and Perspectives in ncRNA Research.Experientia supplementum (2012) · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Meirav SegalHMS Initiative for RNA Medicine, Department of Pathology, Beth, Israel Deaconess Medical Center/Harvard Medical School , Boston, MA, USA.
Frank J SlackHMS Initiative for RNA Medicine, Department of Pathology, Beth, Israel Deaconess Medical Center/Harvard Medical School , Boston, MA, USA.

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2015 to 2026
$31.1M
Precision microRNA medicine in cancerR35CA232105 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SLACK, FRANK J. · 2019 to 2025
$7.2M
NCI NIH HHS P50 CA196530NCI NIH HHS R35 CA232105
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DesignGene Expression Regulation, NeoplasticHumansMicroRNAsNeoplasmsMicroRNAsdeliveryMicrornamiRNAnanoparticleoligonucleotideoncogenetumor suppressor

Identifiers

PMID32421364
PMCPMC7415578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.